The Treatment of Prostate Cancer.
暂无分享,去创建一个
[1] P. Walsh,et al. Nerve grafts are rarely necessary and are unlikely to improve sexual function in men undergoing anatomic radical prostatectomy. , 2001, Urology.
[2] P. Scardino,et al. Bilateral nerve graft during radical retropubic prostatectomy: 1-year followup. , 2001, The Journal of urology.
[3] J. Manola,et al. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. , 2001, Urology.
[4] K. Shinohara,et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Shabsigh,et al. Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. , 2000, Journal of Urology.
[6] M. Lotze,et al. © 2000 Cancer Research Campaign , 2022 .
[7] P. Walsh,et al. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. , 2000, The Journal of urology.
[8] B. Tombal,et al. Intermittent endocrine treatment , 2000, World Journal of Urology.
[9] S. Friis,et al. The need for hospital care of patients with clinically localized prostate cancer managed by noncurative intent: a population based registry study. , 2000, The Journal of urology.
[10] M. Litwin,et al. Quality of life outcomes after brachytherapy for early stage prostate cancer. , 2000, The Journal of urology.
[11] B. Guillonneau,et al. Laparoscopic radical prostatectomy: the Montsouris experience. , 2000, The Journal of urology.
[12] F. Boccardo,et al. Comparison of an LH–RH Analogue (Goeserelin Acetate, ‘Zoladex’) with Combined Androgen Blockade in Advanced Prostate Cancer: Final Survival Results of an International Multicentre Randomized–Trial , 2000, European Urology.
[13] R A Stephenson,et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. , 2000, JAMA.
[14] G. Hanks. Conformal radiotherapy for prostate cancer , 2000, Annals of medicine.
[15] M. Weir,et al. A comparison of the relative merits of radical perineal and radical retropubic prostatectomy , 2000, BJU international.
[16] R. Badalament,et al. Patient-reported complications after cryoablation therapy for prostate cancer. , 1999, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.
[17] P. V. Van Veldhuizen,et al. Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength. , 2000, The Journal of urology.
[18] C. Reddy,et al. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. , 2000, Urology.
[19] H. Ragde,et al. Brachytherapy for clinically localized prostate cancer. , 2000, Seminars in surgical oncology.
[20] M. Benson,et al. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience. , 2000, Urology.
[21] J. Manola,et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.
[22] L. Lacombe,et al. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. , 1999, The Journal of urology.
[23] L. Einhorn,et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] P. Kantoff,et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Pollack,et al. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. , 1999, International journal of radiation oncology, biology, physics.
[26] E. Small,et al. The Treatment of Advanced Prostate Cancer with Ketoconazole , 1999, Drug safety.
[27] G. Kolvenbag,et al. Bicalutamide dosages used in the treatment of prostate cancer , 1999, The Prostate.
[28] Lee,et al. Neoadjuvant hormonal therapy in carcinoma of the prostate , 1999, BJU international.
[29] Schröder,et al. Endocrine treatment of prostate cancer — recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side‐effects , 1999, BJU international.
[30] P. Scardino,et al. Interposition of sural nerve restores function of cavernous nerves resected during radical prostatectomy. , 1999, The Journal of urology.
[31] A. Agarwal,et al. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). , 1999, Urology.
[32] H. Ragde,et al. Ten‐year disease free survival after transperineal sonography‐guided iodine‐125 brachytherapy with or without 45‐gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate carcinoma , 1999, Cancer.
[33] W. Catalona,et al. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. , 1998, The Journal of urology.
[34] I. Thompson,et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.
[35] M. Toublanc,et al. Radical prostatectomy for prostate cancer: the perineal approach increases the risk of surgically induced positive margins and capsular incisions. , 1998, The Journal of urology.
[36] R. DiPaola,et al. Clinical and Biologic Activity of an Estrogenic Herbal Combination (PC-SPES) in Prostate Cancer , 1998 .
[37] A. Renshaw,et al. Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .
[38] Reinhard W. Schulte,et al. Conformal proton therapy for prostate carcinoma. , 1998, International journal of radiation oncology, biology, physics.
[39] Kathleen A. Moon,et al. Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. , 1998, The Journal of urology.
[40] J. Doyle,et al. Prostate cryoablation: Update 1998 , 1998, CA: a cancer journal for clinicians.
[41] C. Atkinson,et al. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. , 1998, The Journal of urology.
[42] H. Ragde,et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides , 1998, The Prostate.
[43] K. Wallner,et al. Clinical course of rectal bleeding following I-125 prostate brachytherapy. , 1998, International journal of radiation oncology, biology, physics.
[44] J. Slater,et al. Particle beam radiation therapy in prostate cancer: is there an advantage? , 1998, Seminars in Radiation Oncology.
[45] J. Klijn,et al. Maximum Androgen Blockade Using LHRH Agonist Buserelin in Combination with Short-Term (Two Weeks) or Long-Term (Continuous) Cyproterone Acetate Is Not Superior to Standard Androgen Deprivation in the Treatment of Advanced Prostate Cancer , 1998, European Urology.
[46] R. Sylvester,et al. Maximal Androgen Blockade: Final Analysis of EORTC Phase III Trial 30853 , 1998, European Urology.
[47] D. Theodorescu,et al. Early prostate-specific antigen failure following radical perineal versus retropubic prostatectomy: the importance of seminal vesicle excision. , 1998, Urology.
[48] J. Guiter,et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. , 1998, European urology.
[49] J. Adolfsson,et al. Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series. , 1998, Urology.
[50] L R Kavoussi,et al. Laparoscopic radical prostatectomy: initial short-term experience. , 1997, Urology.
[51] W. Akerley,et al. Prostate-Specific Antigen Response to Withdrawal of Megestrol Acetate in a Patient With Hormone-Refractory Prostate Cancer , 1997 .
[52] S. Litwin,et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] J. Blasko,et al. Interstitial iodine‐125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma , 1997, Cancer.
[54] C. Mettlin,et al. Changes in patterns of prostate cancer care in the United States: Results of American College of Surgeons Commission on Cancer Studies, 1974–1993 , 1997, The Prostate.
[55] M. Piérart,et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.
[56] M. Zelefsky,et al. Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer. , 1997, The Journal of urology.
[57] P. Schellhammer,et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. , 1997, The Journal of urology.
[58] M. Kattan,et al. Risk factors for complications and morbidity after radical retropubic prostatectomy. , 1997, The Journal of urology.
[59] E. Small,et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. , 1997, The Journal of urology.
[60] L. Holmberg,et al. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. , 1997, JAMA.
[61] R. A. Jones,et al. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. , 1997, British journal of urology.
[62] Daniel W. Miller,et al. Combined proton and photon conformal radiation therapy for locally advanced carcinoma of the prostate: preliminary results of a phase I/II study. , 1997, International journal of radiation oncology, biology, physics.
[63] Mohamed Bidair,et al. Review: Cryoablation for carcinoma of the prostate , 1996 .
[64] P. Carroll,et al. Should cryosurgery be considered a therapeutic option in localized prostate cancer? , 1996, The Urologic clinics of North America.
[65] M. Kattan,et al. Risk factors for urinary incontinence after radical prostatectomy. , 1996, The Journal of urology.
[66] G. Hanks. Long-term control of prostate cancer with radiation. Past, present, and future. , 1996, The Urologic clinics of North America.
[67] P. Scardino,et al. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. , 1996, The Urologic clinics of North America.
[68] W. Fair,et al. Neoadjuvant therapy prior to radical prostatectomy: pro. , 1996, Urology.
[69] P. Schellhammer,et al. Results of radical prostatectomy in men with clinically localized prostate cancer. , 1996, JAMA.
[70] D. Osoba,et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] A. Belldegrun,et al. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] J. Oesterling,et al. Radical prostatectomy: the retropubic approach. , 1996, Urology.
[73] M. Resnick. Radical prostatectomy: the perineal approach. , 1996, Urology.
[74] M. Soloway,et al. The role of induction androgen deprivation prior to radical prostatectomy. , 1996, European urology.
[75] O. Sartor,et al. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer : toxicity and response , 1996, Cancer Chemotherapy and Pharmacology.
[76] E. Crawford,et al. Estrogens in the treatment of prostate cancer. , 1995, The Journal of urology.
[77] C. Coogan,et al. Percutaneous cryoablation of the prostate: preliminary results after 95 procedures. , 1995, The Journal of urology.
[78] J. Nelson,et al. Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate , 1995, Nature Medicine.
[79] R. Weichselbaum,et al. Photon neutron mixed-beam radiotherapy of locally advanced prostate cancer. , 1995, International journal of radiation oncology, biology, physics.
[80] D. Fryback,et al. Long-term survival among men with conservatively treated localized prostate cancer. , 1995, JAMA.
[81] J. Hugosson,et al. Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. , 1995, The Journal of urology.
[82] R. Amato,et al. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. , 1995, Urologic oncology.
[83] P. Schellhammer,et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. , 1995, Urology.
[84] F Lee,et al. Prostate cancer: US-guided percutaneous cryoablation. Work in progress. , 1995, Radiology.
[85] J. Oesterling,et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.
[86] A. Zietman,et al. Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor. , 1994, The Journal of urology.
[87] G. Chodak. The role of watchful waiting in the management of localized prostate cancer. , 1994, The Journal of urology.
[88] J. Cohen,et al. Percutaneous transperineal cryosurgical ablation of the prostate for the primary treatment of clinical stage C adenocarcinoma of the prostate. , 1994, Urology.
[89] W. Catalona,et al. Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy. , 1993, The Journal of urology.
[90] Boris Rubinsky,et al. Transrectal ultrasound‐guided percutaneous radical cryosurgical ablation of the prostate , 1993, Cancer.
[91] Dale McLerran,et al. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. , 1993, JAMA.
[92] H. Scher,et al. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. , 1993, The Journal of urology.
[93] L. Denis,et al. Ketoconazole and liarozole in the treatment of advanced prostatic cancer , 1993, Cancer.
[94] E. Crawford,et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. , 1993, The Journal of urology.
[95] A. Herder,et al. Radical retropubic prostatectomy for localised prostatic carcinoma: a clinical and pathological study of 201 cases. , 1993, Scandinavian journal of urology and nephrology.
[96] P. Walther. Radical perineal vs. retropubic prostatectomy: a review of optimal application and technical considerations in the utilization of these exposures. , 1993, European urology.
[97] S. Steinberg,et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] H. Scher,et al. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. , 1992, The Journal of urology.
[99] D. Paulson,et al. Radical prostatectomy: the pros and cons of the perineal versus retropubic approach. , 1992, The Journal of urology.
[100] G. Hanks. Radiotherapy or surgery for prostate cancer? Ten and fifteen-year results of external beam therapy. , 1991, Acta oncologica.
[101] J. Cohen,et al. US characteristics of frozen prostate. , 1988, Radiology.
[102] J. Woodburn,et al. Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses , 1988, Journal of endocrinological investigation.
[103] P. Walsh,et al. Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. , 1986, The Journal of urology.
[104] M. Blute,et al. Long-term followup of young patients with stage A adenocarcinoma of the prostate. , 1986, The Journal of urology.
[105] W Hinshaw,et al. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. , 1982, The Journal of urology.
[106] D. Byar. The veterans administration cooperative urological research group's studies of cancer of the prostate , 1973, Cancer.
[107] A. Schally,et al. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. , 1971, Biochemical and biophysical research communications.
[108] W. A. Soanes,et al. Use of cryosurgery in prostatic cancer. , 1968, The Journal of urology.
[109] W. Baum,et al. Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases. , 1950, Journal of the American Medical Association.
[110] R. Robinson,et al. Œstrogenic Activity of Certain Synthetic Compounds , 1938, Nature.